All relevant data are within the paper and its Supporting Information files.

Importance of the study {#sec001}
=======================

Effector and memory T cells play a crucial role in HIV infection and are well-preserved in controllers, but become exhausted during infection. Stem cell like memory (T~SCM~) cells are a subset of T cells that possess long half-life, self-renewal capacity and contribute a significant barrier to HIV eradication. The present study demonstrated increased CD8^+^ T cell mediated viral inhibition of different clades of HIV-1 viruses and higher frequencies of peripheral T~SCM~ cells in volunteers who received a subtype C prophylactic HIV-1 vaccine candidate that was tested in a Phase I trial in India. Our findings indicate that the vaccine candidate and vaccination regimen used in the trial were capable of eliciting a favourable antiviral response and inducing production of CD8^+^ T cells and T~SCM~ cells that offer further promise for future HIV vaccine research.

Introduction {#sec002}
============

HIV/AIDS continues to be a significant challenge for global public health even after 35 years of its discovery, with HIV's sequence diversity and rapid evolution being major obstacles for successful vaccine development \[[@pone.0229461.ref001]\]. Though several significant advances have been made with respect to the design and development of HIV vaccines, there have not been any major breakthroughs in the field \[[@pone.0229461.ref002]\]. To date, only one candidate vaccine tested in the RV144 trial in Thailand, demonstrated the ability to significantly reduce the risk of HIV-1 acquisition, giving a modest protective efficacy of 31%, providing new hope for antibody-based vaccine development \[[@pone.0229461.ref003]\].

There is strong evidence to suggest that T cell-mediated responses play an important role in suppression of virus replication and clearance of infected cells from the host \[[@pone.0229461.ref004]--[@pone.0229461.ref006]\]. Several cohort studies have reported that generation and proliferation of HIV-specific CD8^+^ T cells correlate inversely with viral load \[[@pone.0229461.ref007]--[@pone.0229461.ref010]\]. Thus, CD8^+^ T cell-mediated immune responses are clearly capable of modulating the course of HIV infection and therefore constitute an important dimension for vaccine research. Persistence and maintenance of the CD8^+^ T cell response are dependent on CD4^+^ T cell help \[[@pone.0229461.ref011]\]. However, a recent study reported that naturally activated CD8^+^ T cells may persist in the absence of CD4^+^ T cells \[[@pone.0229461.ref012]\] and that a persistent memory CD8^+^ T cell response is important for viral control \[[@pone.0229461.ref013]--[@pone.0229461.ref017]\]. Long-lived memory CTLs can directly kill cells infected with intracellular pathogens by producing cytokines, chemokines (IL-2, IFN-γ, TNF-α, MIP-1) and cytotoxins (perforin, granzymes and granulysin). CTLs can also use the Fas ligand that binds to the Fas receptors present on the surface of many cell types and induce cellular apoptosis \[[@pone.0229461.ref018]\].

Recent studies have identified a subset of memory T cells that possess stem cell-like properties, called stem-like memory T cells (T~SCM~) \[[@pone.0229461.ref019]--[@pone.0229461.ref021]\]. T~SCM~ cells are the least differentiated among the distinct memory populations. They differentiate into different types of memory T cells that play vital roles in controlling the immune response \[[@pone.0229461.ref019]\]. T~SCM~ cells have been well characterized in cancers and other autoimmune diseases. CD8^+^ T~SCM~ cells have been proposed as therapeutic targets in acquired aplastic anaemia \[[@pone.0229461.ref022]\]. However, the role of CD4^+^ and CD8^+^ T~SCM~ cells in HIV infection and vaccination, and their contribution to antiviral immune defence remains unclear. Earlier studies reported that the frequency of CD8^+^ memory T cells (central and effector memory cells) correlates with lower viral load in chronic HIV infection \[[@pone.0229461.ref023]--[@pone.0229461.ref025]\] and that lower levels of expression of PD-1 on these cells \[[@pone.0229461.ref026]--[@pone.0229461.ref028]\] indicate that long-lived memory cells may be derived from T~SCM~ cells. Thus, measuring vaccine-induced T~SCM~ cells could provide key insights into the ability of the vaccine to elicit robust and persistent cellular immune responses.

Characterization of the nature of the antiviral response elicited by vaccination would provide the most critical clues to understanding the exact mechanisms that contribute to vaccine efficacy. Assays that measure CD8^+^ T cell-mediated inhibition of replication of diverse HIV-1 isolates (viral inhibition assay/VIA) may be used to assess the breadth of the direct antiviral function of these cells \[[@pone.0229461.ref029]\].

Previously, we examined vaccine-induced humoral and cell-mediated responses to the same subtype C HIV-1 vaccine (ADVAX DNA prime and MVA boost) tested in a phase I clinical trial in India (P001 trial) and reported encouraging findings \[[@pone.0229461.ref030], [@pone.0229461.ref031]\]. In the current study, we investigated vaccine-induced peripheral T~SCM~ cells and *in vitro* viral inhibitory capacity of vaccine-induced CD8^+^ T cells in the same cohort.

Materials and methods {#sec003}
=====================

Samples {#sec004}
-------

The study was performed using cryopreserved peripheral blood mononuclear cells (PBMC) obtained from volunteers who participated in the IAVI sponsored P001 trial conducted during the period 2009--2010 \[[@pone.0229461.ref031]\]. The trial had enrolled a total of 32 HIV-uninfected healthy volunteers at two sites in India: 16 volunteers at the National Institute for Research in Tuberculosis (NIRT), Chennai, and 16 volunteers at the National AIDS Research Institute (NARI), Pune. The present analysis was confined to samples stored at NIRT alone and focuses on Chennai participants. The 16 individuals (9 males and 7 females) were randomly assigned to either Group A or B, with eight participants in each Group. Group A participants received two intramuscular (I.M.) injections of ADVAX or placebo at baseline (time '0') and 1 month, followed by two I.M. injections of TBC-M4 or placebo at months 3 and 6. Group B participants received three I.M. injections of TBC-M4 or placebo at time 0, months 1 and 6. Among the 8 volunteers in each Group, 6 received the vaccine and 2 received placebo ([Fig 1](#pone.0229461.g001){ref-type="fig"}).

![Vaccination schedule followed in the IAVI Phase-I prime-boost HIV-1 subtype C prophylactic vaccine trial (P001 trial).](pone.0229461.g001){#pone.0229461.g001}

Candidate vaccines {#sec005}
------------------

ADVAX is a DNA vaccine formulated by the Aaron Diamond AIDS Research Center (ADARC), New York, USA, and manufactured by Vical Inc., San Diego, CA, USA (Lot\# 04030248), utilizing the structural features of the commercial plasmid backbone pVAX1 \[[@pone.0229461.ref032], [@pone.0229461.ref033]\]. The vaccine contains two plasmid constructs (one plasmid cloned with the coding sequences of *gag* and *env* genes of the Chinese HIV-1 clade B/C strain and the other one cloned with the coding sequences of *nef/tat* and *pol*, intended to express a fusion protein) mixed in a 1:1 ratio. The candidate vaccine was suspended in sterile phosphate-buffered saline with 0.01M sodium phosphate and 150 mM sodium chloride and was formulated to contain 4 mg of the DNA in a total volume of 1mL.

TBC-M4 is a vaccine manufactured by Therion Biologics Corporation, Cambridge, MA, USA (Lot\# 1B). It is a recombinant Modified Vaccinia Ankara (MVA) virus containing the coding sequences of *gag*, *env*, *reverse transcriptase (RT)*, *tat*, *rev* and *nef* of an Indian HIV-1 clade C strain \[[@pone.0229461.ref034]\]. The vaccine was suspended in phosphate-buffered saline and 10% glycerol to contain 5x10^6^ PFU in a total volume of 0.5 mL. The amino acid sequence homology between the two vector inserts was found to be greater than 85% (ENV: 87.1%; GAG: 95%; POL/RT: 96.4%).

Virus inhibition assay {#sec006}
----------------------

### Viruses {#sec007}

HIV-1 subtype A (U455), subtype B (IIIB), subtype C (247FV2), subtype D (CBL4) and subtype AD (ELI) isolates were used in the VIA. U455 and CBL-4 were obtained from NIBSC, UK, ELI and IIIB were obtained from the NIH AIDS Research and Reference Reagent Program (Bethesda, MD), 247FV2 was kindly provided by George Shaw (University of Pennsylvania, PA). The titer of each viral isolate was determined by end-point dilution and defined as 50% tissue culture infectious dose (TCID~50~) using the TZM-bl cell line \[[@pone.0229461.ref029]\] obtained from the NIH AIDS Research and Reference Reagent Program.

### Expansion of CD4^+^ and CD8^+^ T cells {#sec008}

PBMC were thawed and resuspended at 1--1.5×10^6^ cells/ml in RPMI containing 10% Fetal Bovine Serum (FBS), 50 units IL-2 (R10/50) and 0.5μg/ml CD3^+^/CD4^+^ or CD3^+^/CD8^+^ bi-specific antibody for expansion of CD8^+^ and CD4^+^ T cell sub-populations respectively. Culture volumes were doubled at days 3 and 6 with R10/50 medium. Overall, the cell numbers increased by a factor of mean 5, and the typical purity of day 7 cultures was 97 and 87% for CD4^+^ and CD8^+^ T cells respectively, demonstrating positive expansion and enrichment (≥90% of the CD3+ T cells in culture) of the required T cell sub-population \[[@pone.0229461.ref029]\].

### Viral inhibition assay {#sec009}

Viral inhibition assay was performed as described by Spentzou et al., 2010. Briefly, separate cultures of 7 day-expanded CD4^+^ T cells infected with different HIV-1 isolates at a multiplicity of infection (MOI) of 0.01 were established. To limit variation due to the possible effects of the vaccine regimen on CD4^+^ target cells, a single population of target CD4^+^ T cells was generated for each subject; wherever available, this cell population was generated from the baseline pre-vaccination sample. Virus-infected target cells were co-cultured with autologous CD8^+^ T cells obtained at the pre-vaccination time point and at two post-vaccination time points. CD4^+^ and CD8^+^ T cells were co cultured in 1:1 ratio. In our assay, 0.5 million viral infected CD4^+^ T cells were co cultured with 0.5 million CD8^+^ T cells. Every 3 to 4 days, half of the culture supernatant was removed and replaced with fresh R10/50 medium and assessed for Gag p24 content using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (PerkinElmer, United Kingdom). CD8^+^ T cell-mediated inhibition was expressed as log~10~ reduction in the p24 content of day 13 supernatants from CD8^+^ and CD4^+^ T cell co-cultures as compared to that of CD4+ T cells alone.

Cut-offs were defined by the 97.5th percentile of the baseline VIA response as estimated using PROC QUANTREG in SAS 9.2 (SAS Institute Inc., Cary, NC). VIA response for each virus was defined as positive if the following three criteria were fulfilled: (i) log~10~ inhibition is greater than 1.5 for all HIV-1 isolates, (ii) pre-vaccination response for the same virus is negative, and (iii) the difference between the post-vaccination and pre-vaccination response is ≥0.6 log~10~ inhibition \[[@pone.0229461.ref029]\].

Polychromatic flow cytometric analysis of memory T cells and T~SCM~ cells {#sec010}
-------------------------------------------------------------------------

Cryopreserved PBMC obtained at pre-vaccination, on the day of second MVA vaccination (VAC II), one week after second vaccination, on the day of last MVA vaccination (VAC III) and 1, 2 and 48 weeks after last MVA vaccination, were analyzed for memory T cell subset phenotypes. PBMC at pre-vaccination, one week after VAC II, one week after VAC III, and 2 and 48 weeks after last MVA vaccination were analyzed for T~SCM~ cell phenotype. Two million PBMC were washed with FACS buffer and stained with Live/Dead Fixable Aqua blue dye (Invitrogen). The following cocktail of monoclonal antibodies were used to enumerate the different cell types: T Memory and T~SCM~ cell panel: anti-CD3-APCH7, anti-CD122-PE, anti-CD4-PERCP, anti-CD28-FITC, anti-CD95-PECF594, anti-CD45RA-APC, anti-CCR7-PECY7, and anti-CD8-APCR700. All antibodies were procured from Becton-Dickinson, India ([S1 Table](#pone.0229461.s002){ref-type="supplementary-material"}). Cells were stained for 30 minutes in the dark, washed and fixed with 4% paraformaldehyde for 5 minutes, and acquired on a FACS ARIA SORP flow cytometer (Becton Dickinson). A minimum of 1,000,000 total events were acquired and data were analyzed using FlowJo software, version 10.4 (Treestar, Ashland, OR).

The following panels were used to identify the different memory subsets \[[@pone.0229461.ref019]\]. Naïve cells---CD45RO- CCR7+ CD28+ CD95-, Stem cell-like memory cells---CD45RO- CCR7+ CD28+ CD95+, Central memory cells---CD45RO+ CCR7+ CD28+ CD95+, Effector memory cells---CD45RO+ CCR7- CD28- CD95+, Terminal Memory cells---CD45RO+CCR7- CD28+ CD95+, and terminal effector cells---CD45RO-CCR7- CD28- CD122-CD95+.

Statistics {#sec011}
----------

Statistical analyses were performed using GraphPad Prism, version 7.05 (GraphPad Software, Inc., CA). Values are presented as median and interquartile ranges. The percentage frequency of Memory T cells and T~SCM~ cells were compared within the placebo and Group A and Group B vaccinees at different time points using Kruskal-Wallis test, followed by subgroup analysis using Dunn's multiple comparison test to identify differences between the groups. For all analyses, differences were considered significant if p value was \<0.05.

Ethics statement {#sec012}
----------------

The present study was approved by the Institutional Ethics Committee of NIRT (NIRT IEC No. 2015013). During the trial, written statements of informed consent were obtained from the study volunteers. The trial was supervised by the research personnel of the International AIDS Vaccine Initiative (IAVI) and the study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki \[[@pone.0229461.ref016]\], Guidelines for Good Clinical Practice (GCP) framed in the International Conference on Harmonization (ICH), and Good Clinical Laboratory Practice (GCLP) outlined by the Research Quality Association (RQA), UK, were adhered to during the conduct of the study.

Results {#sec013}
=======

Assessment of viral inhibition activity {#sec014}
---------------------------------------

Viral inhibition activity was assessed with five HIV-1 isolates belonging to different clades, at three-time points (baseline, two weeks post 1^st^ MVA vaccination and two weeks post last MVA vaccination). VIA response was absent in the placebo group at all-time points and in the vaccinated individuals at baseline/pre-vaccination. Positive VIA responses were observed in Group A and B vaccinees post-vaccination. The VIA responses were more frequent in Group A as compared to Group B at two weeks post 1^st^ MVA vaccination; 4 of the 6 Group A volunteers inhibited the U455 isolate (\>1.5log inhibition), 2 volunteers inhibited 247FV2, one individual inhibited IIIB and one individual inhibited ELI-1 with log~10~ reduction in p24 level of \>1.5. In contrast, only one individual in Group B demonstrated VIA activity against the U455 isolate. At two weeks post last MVA vaccination, Group A volunteers exhibited VIA activity against all 5 HIV isolates tested; 3 individuals inhibited the U455 isolate, 2 individuals inhibited IIIB, and 3 individuals inhibited the 247FV2, CBL4 and ELI-1 isolates at \>1.5log. However, in Group B, VIA activity was seen only against two of the HIV isolates; 2 volunteers inhibited U455 and 1 volunteer inhibited CBL4 at \>1.5log. Overall, we observed much better VIA responses in group A volunteers as compared to group B and placebo. These observations suggest that the heterologous prime-boost vaccine regimen was more potent in eliciting a CD8^+^ T cell-dependent antiviral response against different HIV isolates ([Fig 2](#pone.0229461.g002){ref-type="fig"}).

![Viral inhibition activity in terms of log~10~ reduction in p24 level at pre-vaccination, two weeks post first MVA vaccination and two weeks post last MVA vaccination against the five HIV-1 subtypes: 247FV2 (clade C), CBL-4 (clade D), ELI (clade A/D), IIIB (clade B) and U455 (clade A).\
(A) Viral inhibition activity at the pre-vaccination time point. (B) Viral inhibition activity at two weeks post first MVA vaccination. (C) Viral inhibition activity at two weeks post last MVA booster. The box and whisker plots summarize the distribution of positive responses (median, 1^st^ and 3^rd^ quartile). The y-axis represents log~10~ reduction in P24 antigen level. Shaded boxes represent placebo values, white boxes represent Group A and black boxes represent group B values. The mean log~10~ values were compared at different time points within the 3 groups for the 5 different viral clades using Kruskal-Wallis test, followed by subgroup analysis using Dunn's multiple comparison test to identify differences between the three groups. For all analyses, differences were considered significant if p value was \<0.05.](pone.0229461.g002){#pone.0229461.g002}

Induction of memory T cells subsets by vaccination {#sec015}
--------------------------------------------------

PBMC were analysed by multicolour flow cytometry to determine vaccine-induced alterations in the frequency of memory T cell subsets \[central memory T cells (CM), effector memory T cells (EM), terminal effector T cells (TE), and naïve T cells (TN)\]. Among CD4+ T cells, CM cells were defined as CD3+CD4+CD45RO+CCR7+, EM cells as CD3+CD4+CD45RO+CCR7-, TE cells as CD3+CD4+CD45RO-CCR7- and TN cells as CD3+CD4+CD45RO-CCR7+. Among the CD8+ T cells, CM cells were defined as CD3+CD8+CD45RO+CCR7+, EM cells as CD3+CD8+CD45RO+CCR7-, TE cells as CD3+CD8+CD45RO-CCR7- and TN cells as CD3+CD8+CD45RO-CCR7+ ([S1 Fig](#pone.0229461.s001){ref-type="supplementary-material"}).

The proportion of CD4^+^ TN cells was found to be lower in Groups A and B at 1^st^ week post VAC-II, VAC-III, 1^st^ week post VAC-III and 2^nd^ week post VAC-III time points as compared to the placebo. Similarly, decreased frequency of CD8^+^ TN cells was observed in the vaccine recipients at post-vaccination time points ([S2](#pone.0229461.s003){ref-type="supplementary-material"} and [S3](#pone.0229461.s004){ref-type="supplementary-material"} Tables). In contrast, the frequency of CD4^+^ CM cells was higher in the vaccinated groups at VAC-II, 1^st^ week post VAC-II and 1^st^ week post VAC-III time points as compared to the control group, while there was no difference in the frequency of CD8^+^ CM cells in any of the three groups.

We observed that both group A and group B vaccines had significantly higher TE cell frequencies in the CD4^+^ as well as CD8^+^ T cell compartments at all post-vaccination time points as compared to the placebo subjects. The increase in CD8^+^ TE cells was found to be significant in Group A at all post-vaccination time points as compared to group B (p = 0.003 to 0.022) ([Fig 3](#pone.0229461.g003){ref-type="fig"}; [S2 Table](#pone.0229461.s003){ref-type="supplementary-material"}). In the CD4 compartment, the frequency of TE cells was found to be significantly higher in group A than in group B at VAC-III and 1^st^ week post VAC-III time points only (p = 0.009; p = 0.001) ([Fig 4](#pone.0229461.g004){ref-type="fig"}; [S3 Table](#pone.0229461.s004){ref-type="supplementary-material"}).

![CD8^+^ memory T cell subsets in placebo, Group A and Group B volunteers.\
Frequency (%) of total CD8^+^ memory T cell subsets in Placebo, Group A and Group B volunteers at Pre-vaccination, one week post VAC-II, and one, two and 48 weeks post VAC-III. The superimposed dot plots summarize the % frequency of total vaccine-induced CD8^+^ memory T cell subsets.](pone.0229461.g003){#pone.0229461.g003}

![CD4^+^ Memory T cell subsets in placebo, Group A and Group B volunteers.\
Frequency (%) of total CD4^+^ memory T cell subsets in Placebo, Group A and Group B at Pre-vaccination, one week post VAC-II, and one, two and 48 weeks post VAC-III. The superimposed dot plots summarize the % frequency of total CD4^+^ memory T cell subsets.](pone.0229461.g004){#pone.0229461.g004}

Similarly, significantly elevated numbers of EM T cells was seen in Group A as compared to Group B and placebo controls. The increase in CD8^+^ EM cells was found to be significantly higher in Group A at all post-vaccination time points when compared to placebo as well as group B (Group A vs Placebo: p\<0.001 to 0.009; Group A vs group B: p = 0.002 to 0.039) ([Fig 3](#pone.0229461.g003){ref-type="fig"}; [S2 Table](#pone.0229461.s003){ref-type="supplementary-material"}). CD4^+^ EM cells were significantly higher in group A at all post-vaccination time points except VAC III and 2^nd^ week post VAC-III as compared to placebo (p = 0.019 to 0.007). However, when compared to group B, the increase was significant only at the VAC-II time point (p = 0.019). Group B volunteers had increased frequency of CD4^+^ EM cells at 1^st^ week post VAC-II, 2^nd^ week post VAC-III and 48^th^ week post VAC-III as compared to placebo (p = 0.002; p = 0.0006; p = 0.008 respectively) ([Fig 4](#pone.0229461.g004){ref-type="fig"}; [S3 Table](#pone.0229461.s004){ref-type="supplementary-material"}). Difference in the number of total CD8^+^ and CD4^+^ memory T cell subsets is presented in [S4](#pone.0229461.s005){ref-type="supplementary-material"} and [S5](#pone.0229461.s006){ref-type="supplementary-material"} Tables respectively. These observations indicate that both the heterologous and homologous prime-boost vaccination regimens resulted in increased frequencies of peripheral effector and memory CD4^+^ and CD8^+^ T cells, with the increase being significantly higher in group A as compared to group B.

Induction of T~SCM~ cells by vaccination {#sec016}
----------------------------------------

CD4+ T~SCM~ cells were defined as CD3+CD4+CD45RO-CCR7+CD28+CD95+ cells and CD8+ T~SCM~ cells were defined and identified as CD3+CD8+CD45RO-CCR7+CD28+CD95+ cells ([S1 Fig](#pone.0229461.s001){ref-type="supplementary-material"}). The percentage of circulating CD4^+^ or CD8^+^ T~SCM~ cells were relatively small (0.15 to 0.22%) in the placebo group as well as at baseline in the vaccinated groups. Vaccination resulted in a significant increase in the frequency of T~SCM~ cells in both CD4^+^ and CD8^+^ T cell compartments in both Groups A and B ([Table 1A](#pone.0229461.t001){ref-type="table"}; Figs [5](#pone.0229461.g005){ref-type="fig"} and [6](#pone.0229461.g006){ref-type="fig"}). CD8^+^ T~SCM~ cell frequency was significantly higher in Group A at all post-vaccination time points as compared to the placebo group (p\<0.001 to 0.003), at one week post VAC-II and III, and 48 weeks post VAC-III, as compared to Group B (p = 0.005 to 0.025) ([Fig 6](#pone.0229461.g006){ref-type="fig"}). CD4^+^ T~SCM~ cell frequencies were significantly higher in Group A at one week post VAC-II and one week post VAC-III time points as compared to placebo (p≤0.002), and at one week post VAC-II when compared to Group B volunteers (p = 0.025) ([Table 1B](#pone.0229461.t001){ref-type="table"}; [Fig 6](#pone.0229461.g006){ref-type="fig"}). There was a clear trend towards increased frequencies of this sub-population of cells in Group A volunteers during the period of vaccination ([Fig 5](#pone.0229461.g005){ref-type="fig"}), suggesting that the ADVAX/MVA prime-boost regimen induced high frequencies of CD8^+^ and CD4^+^ T~SCM~ cells.

![CD4^+^ T~SCM~ cell subsets in placebo, Group A and Group B volunteers.\
Frequency (%) of total circulating CD4^+^ T~SCM~ cells in Placebo, Group A and Group B at Pre-vaccination, one week post VAC-II, and one, two and 48 weeks post VAC-III. The box and whisker plots summarize the % frequency of circulating CD4+ T~SCM~ cells (median, 1^st^ and 3^rd^ quartiles). K-Wallis test was performed to analyze differences within the individual groups, and Dunn's multiple comparison test was performed to identify differences between the 3 groups. P---Placebo; A---Group A; B---Group B; \*- p\<0.05; \*\*- p\<0.01; \*\*---p\<0.001.](pone.0229461.g005){#pone.0229461.g005}

![CD8^+^ T~SCM~ cell subsets in placebo, Group A and Group B volunteers.\
Frequency (%) of total circulating CD8^+^ T~SCM~ cells in Placebo, Group A and Group B at Pre-vaccination, one week post VAC-II, and one, two and 48 weeks post VAC-III. The box and whisker plots summarize the % frequency of circulating CD8^+^ T~SCM~ cells (median, 1^st^ and 3^rd^ quartiles). K-Wallis test was performed to analyze differences within the individual groups, and Dunn's multiple comparison test was performed to identify differences between the 3 groups. P---Placebo; A---Group A; B---Group B; \*- p\<0.05; \*\*- p\<0.01; \*\*\*- p\<0.001.](pone.0229461.g006){#pone.0229461.g006}

10.1371/journal.pone.0229461.t001

###### Induction of T~SCM~ cells by vaccination.

A\) Comparison of mean frequency (%) of CD4^+^ T~SCM~ cells in Placebo, Group A and Group B volunteers. B) Comparison of mean frequency of CD8^+^ T~SCM~ cells in Placebo, Group A and Group B volunteers.

![](pone.0229461.t001){#pone.0229461.t001g}

  ----------------------- ----------------------------------------- ----------------------------------------------- ------------------------ ------- ------------------------------------
  **A**                                                                                                                                              
  **Time**                **CD4**^**+**^ **T**~**SCM**~ **cells**   **Sig.**[\*](#t001fn001){ref-type="table-fn"}   **Sub-group analysis**           
  **Placebo P (n = 4)**   **Group A (n = 6)**                       **Group B (n = 6)**                                                              
  **median (IQR)**        **median (IQR)**                          **median (IQR)**                                                                 
  Pre-VAC                 0.15 (0.11--0.18)                         0.19 (0.15--0.22)                               0.18 (0.15--0.21)        0.247   \-
  VAC-II+1W               0.18 (0.16--0.21)                         1.38 (1.02--1.65)                               0.77 (0.52--0.97)        0.005   A vs. P (\<0.001); B vs. P 0.025)
  VAC-III+1W              0.16 (0.09--0.20)                         1.37 (0.46--1.63)                               0.69 (0.34--0.91)        0.018   A vs. P (0.002)
  VAC-III+2W              0.19 (0.16--0.21)                         1.16 (0.19--1.32)                               0.19 (0.17--0.26)        0.191   \-
  VAC-III+48W             0.14 (0.13--0.24)                         0.32 (0.15--0.76)                               0.26 (0.18--0.42)        0.118   \-
  **B**                                                                                                                                              
  **Time**                **CD8**^**+**^ **T**~**SCM**~ **cells**   **Sig.**[\*](#t001fn001){ref-type="table-fn"}   **Sub-group analysis**           
  **Placebo P (n = 4)**   **Group A (n = 6)**                       **Group B (n = 6)**                                                              
  **median (IQR)**        **median (IQR)**                          **median (IQR)**                                                                 
  Pre-VAC                 0.17 (0.13--0.27)                         0.22(0.17--0.32)                                0.18 (0.13--0.24)        0.428   \-
  VAC-II+1W               0.21 (0.08--0.26)                         1.38 (0.87--1.89)                               0.96 (0.60--1.05)        0.008   A vs. P (0.001); B vs. P (0.017)
  VAC-III+1W              0.15 (0.13--0.17)                         1.77 (1.15--2.06)                               0.57 (0.43--1.76)        0.005   A vs. P (\<0.001); B vs. P (0.025)
  VAC-III+2W              0.19 (0.19--0.26)                         2.92 (2.53--3.19)                               1.35 (0.59--1.99)        0.003   A vs. P (\<0.001); A vs. B (0.014)
  VAC-III+48W             0.14 (0.07--0.16)                         1.58 (0.72--1.82)                               1.52 (0.77--1.79)        0.014   A vs. P (0.003); B vs. P (0.005)
  ----------------------- ----------------------------------------- ----------------------------------------------- ------------------------ ------- ------------------------------------

\*K-Wallis test was performed to analyze differences within the individual groups, and Dunn's multiple comparison test was performed to identify differences between the 3 groups.

Discussion {#sec017}
==========

The ultimate solution to the HIV epidemic is a vaccine that will substantially reduce transmission \[[@pone.0229461.ref035]--[@pone.0229461.ref037]\]. The risk of transmission is associated with high levels of viremia seen in acute and uncontrolled chronic infection. Though several studies have documented an inverse correlation between activated immune cells and viral load \[[@pone.0229461.ref003], [@pone.0229461.ref038], [@pone.0229461.ref039]\], their successful incorporation into vaccine design has not been achieved so far \[[@pone.0229461.ref037], [@pone.0229461.ref040]\]. Adaptive T cell immunity provides the individual with a specialized defence against intracellular pathogens. CD8^+^ T cells were first implicated in suppressing HIV replication when reductions in viral load were found to correlate with the appearance of HIV-specific CD8^+^ T cells \[[@pone.0229461.ref041], [@pone.0229461.ref042]\]. Subsequent studies showed that long term non-progressors (LTNP) possess relatively high CTL and CD4^+^ T cell proliferative responses despite low viral loads \[[@pone.0229461.ref042]\]. In SIV infection, removal of CTLs correlated with an increased life span of productively infected CD4^+^ T cells and increased viral load, demonstrating clearly the importance of CTLs in viral control \[[@pone.0229461.ref043]\]. Ongoing efforts to develop an effective HIV vaccine are partly based on the principle that a specific antiviral CTL response is crucial for immune control of viral replication. This principle applies to various chronic and persistent viral infections such as hepatitis B, hepatitis C, CMV and Epstein-Barr virus \[[@pone.0229461.ref003]\].

The IAVI-sponsored Phase I P001 trial conducted in India explored the ability of an HIV-1 subtype C prophylactic vaccine candidate to influence the frequencies of different types of peripheral memory T cells (CM, EM and TE) and T~SCM~ cells in volunteers. We observed that both the heterologous and homologous prime-boost vaccine regimens induced changes in proportions of CM, EM and TE cells in the CD4^+^ as well as CD8^+^ T cell compartments. Changes in the frequency of memory subsets were more pronounced in the CD8^+^ T cell compartment as compared to the CD4^+^ T cell compartment in both vaccinee groups, suggesting that both the ADVAX/MVA and MVA regimens were capable of eliciting memory CD8^+^ T cells responses. These responses were maintained up to 48 weeks post last vaccination, implying that the vaccine-induced memory CD8^+^ T cell response was long-lasting, and could potentially provide long term virological control.

T~SCM~ cells are a subset of T cells that give rise to different populations of memory T cells (CM, EM and TE cells) \[[@pone.0229461.ref044]\]. Functional cellular responses of CMV, Flu, SIV and melanoma-specific CD8^+^ T~SCM~ have been previously reported \[[@pone.0229461.ref020]\]. Though the role of T~SCM~ cells in HIV infection and antiviral response has not been completely elucidated, earlier studies have reported that elite controllers have a higher percentage of effector cells and immature memory HIV-1-specific CD8^+^ T cells \[[@pone.0229461.ref045]--[@pone.0229461.ref047]\]. These studies suggest a role for HIV-1-specific T~SCM~ cells in HIV-1 infection. Interestingly, the proportion of total CD8^+^ T~SCM~ cells was observed to correlate inversely with levels of plasma viremia in untreated HIV-1 infected individuals \[[@pone.0229461.ref048]\]. On the other hand, CD4^+^ T~SCM~ cells, in addition to giving rise to different subsets of memory T cells, also constitute reservoirs for HIV-1 infection. Hence, it may be considered that the generation of CD8^+^ T~SCM~ cells may be a better correlate of protection against HIV infection, as these cells would not be infected with HIV-1. Our study identified a significantly higher proportion of circulating CD8^+^ T~SCM~ cells in volunteers who received the ADVAX and MVA or MVA alone as compared to placebo. The overall frequency of CD4^+^ and CD8^+^ T~SCM~ cells was higher in group A at two weeks post last MVA vaccination as compared to the pre-vaccination time point, suggesting that DNA priming and MVA boosting was more effective in inducing T~SCM~ cells and was capable of generating a long lasting memory and effector response.

CTLs are functionally defined as either polyfunctional CD8^+^ T cells that secrete multiple cytokines \[[@pone.0229461.ref049]\], or highly proliferative CD8^+^ T cells that kill HIV-infected target cells \[[@pone.0229461.ref050]\] and suppress HIV replication *in vitro* \[[@pone.0229461.ref051], [@pone.0229461.ref052]\]. Intracellular cytokine staining (ICS) and IFN-γ ELIS~POT~ assays are routinely employed to evaluate vaccine-induced cellular immune responses. Though these responses do not correlate with *in vivo* virus control, they are helpful in demonstrating magnitudes and specificities of the T cell response. Hence, an assay that directly assesses the breadth of T cell-mediated antiviral activity against different HIV-1 isolates would be best suited to evaluate the potential ability of the vaccine to induce a T cell response that can control virus *in vivo* \[[@pone.0229461.ref029]\].

Previously, we evaluated vaccine-induced T cell responses in these groups of individuals using IFN-γ ELIS~POT~ and ICS assays and reported increased IFN-γ ELIS~POT~ responses in Group A as compared to Group B \[[@pone.0229461.ref031], [@pone.0229461.ref053]\]. We also observed significantly elevated Env and Gag-specific mono- and bi-functional T cell responses in vaccinated individuals, with the magnitude of responses being significantly higher in Group A as compared to Group B \[[@pone.0229461.ref053]\]. In the present study, we analyzed the antiviral response of the vaccine-induced CD8^+^ T cells using the Virus Inhibition Assay. A similar vaccine trial, the P002 trial conducted in the UK with the same vaccine constructs, had reported that CD8^+^ T cell-mediated VIA activity was detected only in Group A against three HIV isolates tested: 247FV2 (clade C), 97ZA012 (clade C), and IIIB (clade B). Further, they reported an increase in the magnitude of the ICS response to HIV proteins in Group A as compared to Group B.

In the present study, CD8^+^ T cell-mediated VIA activity was studied against five HIV isolates, 247FV2 (clade C), ELI-1 (clade A/D), CBL4 (clade D), U455 (clade A) and IIIB (clade B). VIA activity was detected in Group A against four isolates: 247FV2, ELI-1, U455 and IIIB, whereas in Group B VIA activity was observed only against two isolates: U455 and IIIB. Four volunteers exhibited viral inhibition activity at two weeks post first MVA vaccination and 5 volunteers showed viral inhibition activity at two weeks post last MVA vaccination in Group A, while in Group B only 3 volunteers showed VIA response at two weeks post last MVA vaccination alone. Our findings reveal elevated CD8^+^ T cell-mediated VIA activity in terms of breadth as well as magnitude in Group A as compared to Group B. These observations support our earlier findings of significantly higher ICS and IFN-γ ELIS~POT~ responses in Group A volunteers and also reflect the findings of the P002 vaccine trial. Findings of other studies also suggest that the quality of the immune response was enhanced by the DNA prime, when adenovirus or poxvirus vectors were used as the boost \[[@pone.0229461.ref054]--[@pone.0229461.ref056]\]. Polyfunctionality of the T cells and increased numbers of terminally differentiated T cells with a cytotoxic effector potential have been reported in prime-boost vaccine regimens \[[@pone.0229461.ref057], [@pone.0229461.ref058]\]. However, VIA activity is generally not detected after DNA, MVA or canarypox virus prime and protein-boost but may be observed with adenovirus vectors \[[@pone.0229461.ref029], [@pone.0229461.ref059]\].

It is critical that a T cell-based vaccine generates an effective pool of memory CD8^+^ T cells that can respond to acute HIV infection or effectively control chronic HIV replication \[[@pone.0229461.ref060]\]. Our earlier studies reported ADVAX and MVA vaccination-induced both HIV-specific CD4^+^ and CD8^+^ T cells. In the present study, we demonstrated the induction of CD8^+^ T cell-mediated HIV-1 inhibition activity pointing to a potentially protective nature of the CD8^+^ T cell response generated by the DNA prime and MVA boost vaccine regimen. Various studies have reported that T~SCM~ cells are critical for the generation of mature CE, EM and TE cells \[[@pone.0229461.ref019], [@pone.0229461.ref021], [@pone.0229461.ref061], [@pone.0229461.ref062]\]; however, the potential role of these cells in HIV infection and vaccination remains unclear. In the present study, we demonstrated a significant increase in the frequency of both peripheral CD4+ and more prominently CD8^+^ T~SCM~ cells following vaccination with a greater increase elicited by the heterologous DNA/MVA prime-boost regimen, thus clearly demonstrating the further scope for testing the prime-boost vaccine regimen.

Supporting information {#sec018}
======================

###### Representative pseudocolor FACS plot of circulating T stem like memory cells.

CD4^+^ T~SCM~ and CD8^+^ T~SCM~ cells were gated sequentially on singlets, lymphocyte-sized cells, live CD3^+^ T cells, CD4+ T cells, CD8^+^ T cells, and then on memory T cells. Central Memory T cells were defined as CD3+CD4+/CD8+CD45RO+CCR7+, Effector Memory cells as CD3+CD4+/CD8+CD45RO+CCR7-, Terminal Effector cells as CD3+CD4+CD45RO-CCR7- and Naïve T cells as CD3+CD4+/CD8+ CD45RO-CCR7+. T~SCM~ cells were defined as CD3+CD4+/CD8+CD45RO-CCR7+CD28+CD95+.

(PPTX)

###### 

Click here for additional data file.

###### Commercial reagents used for multicolour flow cytometry.

(DOCX)

###### 

Click here for additional data file.

###### Frequency of memory CD8+ T cell subsets.

(DOCX)

###### 

Click here for additional data file.

###### Frequency of memory CD4+ T cell subsets.

(DOCX)

###### 

Click here for additional data file.

###### Total count of memory CD8+ T cells.

(DOCX)

###### 

Click here for additional data file.

###### Total count of memory CD4+ T cells.

(DOCX)

###### 

Click here for additional data file.
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Dear Dr. Luke,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

   Both reviewers had concerns that the data do not in fact support the conclusions as stated. Both reviewers also had concerns with regards to the techniques being utilized and the need for some additional studies to confirm the conclusions reached by the authors. This manuscript therefore requires some additional studies and, in addition, a need to address each of the concerns raised by the 2 reviewers.

We would appreciate receiving your revised manuscript by Feb 03 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Aftab A. Ansari, PhD

Academic Editor
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When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: In this manuscript Ponnan et al., aims to evaluate an T cell responses and TSCM cells in volunteers enrolled in a phase I HIV-1 subtype C prophylactic vaccine trial in India during 2009-2010. Ponnan et al, hereby report novel findings where they interrogated vaccine induced responses and stem cell memory responses in volunteers who received an HIV-1 subtype C prophylactic vaccine candidate primed with ADVAX DNA and later followed by MVA boost versus either MVA alone or placebo. The results obtained in this study revealed that priming with ADVAX DNA followed with MVA boost versus MVA alone resulted in increased frequencies of peripheral CD8+ TSCM cells and augmented CD8+ T cell-mediated inhibition of replication of different HIV-1 clades. Even-though the manuscript is well written, and these finding may have have significance in the development of vaccines that are urgently needed by high risk populations. However, as stated, the true role of TSCM and actual changes that occur during HIV-1 infection is yet to be fully understood. Therefore, in this manuscript additional investigation is required to confirm the true functionality of CD8+ TSCM cells generated after successful HIV-1 subtype C prophylactic vaccine candidate + ADVAX DNA + MVA boost. Therefore, the manuscript lacks critical experiment such as by sorting CD8+TSCM (a) could they have superior virus inhibition following co-culture with autologous infected CD4+ T cells? (b) in comparison to more differentiated memory phenotypes, are there any differences in cytokine patterns in response to HIV-1 specific overlapping peptides? to make any conclusions on the role of TSCM cells in this prophylactic vaccine trial.

Reviewer \#2: In this manuscript, Ponnan and colleagues characterized the phenotype of total CD4 and CD8 T cells, and the ability of in vitro expanded cells to inhibit HIV replication using cells obtained from a HIV vaccine study that was conducted in India many years ago. The authors conclude that cells from vaccinated individuals exhibit some HIV inhibition activity and vaccination induces Tscm cells. Overall, these results are not conclusive and there are some major issues with the analyses as described below.

1\) Need to provide details for CD4 T cell infection assay and indicate the ratio of CD4 and CD8 T cells used for virus inhibition assays.

2\) Fig 2 -- virus inhibition activity is not conclusive. There are no P values and activity was observed even at prevaccination time point (Fig. 2A).

3\) Figs 3-6: The data on characterization of different memory CD4 and CD8 T cells are not conclusive and significant for the following reasons. 1) These should be expressed as a percent of total lymphocytes or converted into absolute number to get some idea about the actual change in the number of these cells over time. Currently, they are presented as a percent of total CD4 or CD8 T cells. This is not appropriate. 2) These are total CD4 or CD8 T cells, not vaccine-specific T cells. 3) Where there is an increase, we don't know if these are MVA or HIV-specific cells. 4) overall, the observed increases are small considering that these are total cells (not antigen-specific).

4\) The authors need to correct for multiple comparisons for P values.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Reviewer \#1: In this manuscript Ponnan et al., aims to evaluate an T cell responses and TSCM cells in volunteers enrolled in a phase I HIV-1 subtype C prophylactic vaccine trial in India during 2009-2010. Ponnan et al, hereby report novel findings where they interrogated vaccine induced responses and stem cell memory responses in volunteers who received an HIV-1 subtype C prophylactic vaccine candidate primed with ADVAX DNA and later followed by MVA boost versus either MVA alone or placebo. The results obtained in this study revealed that priming with ADVAX DNA followed with MVA boost versus MVA alone resulted in increased frequencies of peripheral CD8+ TSCM cells and augmented CD8+ T cell-mediated inhibition of replication of different HIV-1 clades. Even-though the manuscript is well written, and these finding may have have significance in the development of vaccines that are urgently needed by high risk populations.

However, as stated, the true role of TSCM and actual changes that occur during HIV-1 infection is yet to be fully understood. Therefore, in this manuscript additional investigation is required to confirm the true functionality of CD8+ TSCM cells generated after successful HIV-1 subtype C prophylactic vaccine candidate + ADVAX DNA + MVA boost. Therefore, the manuscript lacks critical experiment such as by sorting CD8+TSCM (a) could they have superior virus inhibition following co-culture with autologous infected CD4+ T cells? (b) in comparison to more differentiated memory phenotypes, are there any differences in cytokine patterns in response to HIV-1 specific overlapping peptides? to make any conclusions on the role of TSCM cells in this prophylactic vaccine trial.

• We agree with the reviewer that single cell sorting of CD8+ Tscm cells and their analysis for HIV-1 peptide induced cytokine response as well as virus inhibition activity would be extremely interesting. However, we were not in a position to undertake such experiments due to the limited number of PBMC available for this study. As mentioned in the manuscript, this study has been carried out PBMC stored from volunteers who were vaccinated during the period 2009-2010. Using the limited number of cells that were available we studied several aspects of vaccine-induced cellular and humoral immune responses including polyfunctional T cells, T follicular helper cells, Regulatory T cells, memory T cells, Tscm cells, variable loop antibodies, neutralizing antibodies, virus inhibition activity, etc. We have previously published 2 manuscripts in PLOSone entitled "Induction of circulating T Follicular Helper cells and Regulatory T cells correlating with HIV-1 gp120 variable loop antibodies by a subtype C prophylactic vaccine tested in a Phase I trial in India" (<https://doi.org/10.1371/journal.pone.0055831>) and "Induction and maintenance of bi-functional (IFN-γ + IL-2+ and IL-2+ TNF-α+) T cell responses by DNA prime MVA boosted subtype C prophylactic vaccine tested in a Phase I trial in India" (<https://doi.org/10.1371/journal.pone.0213911>).

Reviewer \#2: In this manuscript, Ponnan and colleagues characterized the phenotype of total CD4 and CD8 T cells, and the ability of in vitro expanded cells to inhibit HIV replication using cells obtained from a HIV vaccine study that was conducted in India many years ago. The authors conclude that cells from vaccinated individuals exhibit some HIV inhibition activity and vaccination induces Tscm cells. Overall, these results are not conclusive and there are some major issues with the analyses as described below.

1\) Need to provide details for CD4 T cell infection assay and indicate the ratio of CD4 and CD8 T cells used for virus inhibition assays.

As suggested by the reviewer, we revisited our description of the VIA assay and the suggested details have been incorporated in the manuscript.

2\) Fig 2 -- virus inhibition activity is not conclusive. There are no P values and activity was observed even at pre vaccination time point (Fig. 2A).

The mean values of log10 reduction was compared at different time points within the placebo, Group A and Group B vaccinees for the 5 different viral clades, using Kruskal-Wallis test followed by subgroup analysis using Dunn's multiple comparison test to identify differences between the three groups. For all analyses, differences were considered significant if p value was \<0.05. The p values have been incorporated in Fig-2.

3\) Figs 3-6: The data on characterization of different memory CD4 and CD8 T cells are not conclusive and significant for the following reasons.

• These should be expressed as a percent of total lymphocytes or converted into absolute number to get some idea about the actual change in the number of these cells over time. Currently, they are presented as a percent of total CD4 or CD8 T cells. This is not appropriate.

According to the reviewer\'s suggestion, we have reanalysed the FACS data and exported absolute count of different subsets of T cells and incorporated as supplementary tables in addition to the percentage frequency of immune cells.

• These are total CD4 or CD8 T cells, not vaccine-specific T cells.

3\) Where there is an increase, we don't know if these are MVA or HIV-specific cells..

4\) overall, the observed increases are small considering that these are total cells (not antigen-specific).

We agree with the reviewer that the CD4 and CD8 T cells are not antigen specific. However, we found the significantly increased frequencies of different memory T cells in the vaccine recipients as compared to the placebo recipients. We therefore assume that the increase in immune cell subsets was vaccine induced.

4\) The authors need to correct for multiple comparisons for P values.

As suggested by the reviewer we revisited statistical analysis. Since the study includes three groups of volunteers (Placebo, Group-A and Group-B) and different timepoints of vaccination, we used Kruskal-Wallis test to compare vaccine induced responses at different time points and followed it up with subgroup analysis using Dunn's multiple comparison test to identify differences between the groups. This has been mentioned in the manuscript.
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Evaluation of antiviral T cell responses and TSCM cells in volunteers enrolled in a phase I HIV-1 subtype C prophylactic vaccine trial in India

PLOS ONE

Dear Dr Luke,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

      Please see the minor comments I have posted in the comments to the authors. I would very much like the authors to address thie minor issue. Otherwise, as I stated, the authors have done the best they can to address the issues raised by the 2 reviewers.

We would appreciate receiving your revised manuscript by Mar 19 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Aftab A. Ansari, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

The authors I believe have done the best they can to address the issues raised by the 2 reviewers. There is only one remaining isue that the authors need to address. In the revised Fig. 2 that appears to be presented out of order, there are only 2 data sets that show asterisk in Fig. 2C ? Are there no other statistically valid differences in the other data presented ? If so, the authors need to modify their manuscript otherwise please edit the figure.

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Reviewer \#1: In this manuscript Ponnan et al., aims to evaluate an T cell responses and TSCM cells in volunteers enrolled in a phase I HIV-1 subtype C prophylactic vaccine trial in India during 2009-2010. Ponnan et al, hereby report novel findings where they interrogated vaccine induced responses and stem cell memory responses in volunteers who received an HIV-1 subtype C prophylactic vaccine candidate primed with ADVAX DNA and later followed by MVA boost versus either MVA alone or placebo. The results obtained in this study revealed that priming with ADVAX DNA followed with MVA boost versus MVA alone resulted in increased frequencies of peripheral CD8+ TSCM cells and augmented CD8+ T cell-mediated inhibition of replication of different HIV-1 clades. Even-though the manuscript is well written, and these finding may have have significance in the development of vaccines that are urgently needed by high risk populations.

However, as stated, the true role of TSCM and actual changes that occur during HIV-1 infection is yet to be fully understood. Therefore, in this manuscript additional investigation is required to confirm the true functionality of CD8+ TSCM cells generated after successful HIV-1 subtype C prophylactic vaccine candidate + ADVAX DNA + MVA boost. Therefore, the manuscript lacks critical experiment such as by sorting CD8+TSCM (a) could they have superior virus inhibition following co-culture with autologous infected CD4+ T cells? (b) in comparison to more differentiated memory phenotypes, are there any differences in cytokine patterns in response to HIV-1 specific overlapping peptides? to make any conclusions on the role of TSCM cells in this prophylactic vaccine trial.

• We agree with the reviewer that single cell sorting of CD8+ Tscm cells and their analysis for HIV-1 peptide induced cytokine response as well as virus inhibition activity would be extremely interesting. However, we were not in a position to undertake such experiments due to the limited number of PBMC available for this study. As mentioned in the manuscript, this study has been carried out PBMC stored from volunteers who were vaccinated during the period 2009-2010. Using the limited number of cells that were available we studied several aspects of vaccine-induced cellular and humoral immune responses including polyfunctional T cells, T follicular helper cells, Regulatory T cells, memory T cells, Tscm cells, variable loop antibodies, neutralizing antibodies, virus inhibition activity, etc. We have previously published 2 manuscripts in PLOSone entitled "Induction of circulating T Follicular Helper cells and Regulatory T cells correlating with HIV-1 gp120 variable loop antibodies by a subtype C prophylactic vaccine tested in a Phase I trial in India" (<https://doi.org/10.1371/journal.pone.0055831>) and "Induction and maintenance of bi-functional (IFN-γ + IL-2+ and IL-2+ TNF-α+) T cell responses by DNA prime MVA boosted subtype C prophylactic vaccine tested in a Phase I trial in India" (<https://doi.org/10.1371/journal.pone.0213911>).

Reviewer \#2: In this manuscript, Ponnan and colleagues characterized the phenotype of total CD4 and CD8 T cells, and the ability of in vitro expanded cells to inhibit HIV replication using cells obtained from a HIV vaccine study that was conducted in India many years ago. The authors conclude that cells from vaccinated individuals exhibit some HIV inhibition activity and vaccination induces Tscm cells. Overall, these results are not conclusive and there are some major issues with the analyses as described below.

1\) Need to provide details for CD4 T cell infection assay and indicate the ratio of CD4 and CD8 T cells used for virus inhibition assays.

As suggested by the reviewer, we revisited our description of the VIA assay and the suggested details have been incorporated in the manuscript.

2\) Fig 2 -- virus inhibition activity is not conclusive. There are no P values and activity was observed even at pre vaccination time point (Fig. 2A).

As suggested, addition to the Mann Whitney test, mean values of log10 reduction was compared at different time points within the placebo, Group A and Group B vaccines for the 5 different viral clades by post Hoc analysis by using Kruskal-Wallis test followed by subgroup analysis using Dunn's multiple comparison test to identify differences between the three groups. For all analyses, differences were considered significant if p value was \<0.05. We found Group A & B was statistically significant against the placebo only in \" U455 viral inhibition at two week post last vaccination\".

3\) Figs 3-6: The data on characterization of different memory CD4 and CD8 T cells are not conclusive and significant for the following reasons.

• These should be expressed as a percent of total lymphocytes or converted into absolute number to get some idea about the actual change in the number of these cells over time. Currently, they are presented as a percent of total CD4 or CD8 T cells. This is not appropriate.

According to the reviewer\'s suggestion, we have reanalysed the FACS data and exported absolute count of different subsets of T cells and incorporated as supplementary tables in addition to the percentage frequency of immune cells.

• These are total CD4 or CD8 T cells, not vaccine-specific T cells.

3\) Where there is an increase, we don't know if these are MVA or HIV-specific cells..

4\) overall, the observed increases are small considering that these are total cells (not antigen-specific).

We agree with the reviewer that the CD4 and CD8 T cells are not antigen specific. However, we found the significantly increased frequencies of different memory T cells in the vaccine recipients as compared to the placebo recipients. We therefore assume that the increase in immune cell subsets was vaccine induced.

4\) The authors need to correct for multiple comparisons for P values.

As suggested by the reviewer we revisited statistical analysis. Since the study includes three groups of volunteers (Placebo, Group-A and Group-B) and different timepoints of vaccination, we used Kruskal-Wallis test to compare vaccine induced responses at different time points and followed it up with subgroup analysis using Dunn's multiple comparison test to identify differences between the groups. This has been mentioned in the manuscript.

Additional Editor Comments (if provided):

The authors I believe have done the best they can to address the issues raised by the 2 reviewers. There is only one remaining isue that the authors need to address. In the revised Fig. 2 that appears to be presented out of order, there are only 2 data sets that show asterisk in Fig. 2C ? Are there no other statistically valid differences in the other data presented ? If so, the authors need to modify their manuscript otherwise please edit the figure.

Suggested modification has been carried out.

###### 

Submitted filename: Responce to the reviewers.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0229461.r005
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Dear Dr. Luke,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Aftab A. Ansari, PhD

Academic Editor

PLOS ONE
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Evaluation of antiviral T cell responses and TSCM cells in volunteers enrolled in a phase I HIV-1 subtype C prophylactic vaccine trial in India

Dear Dr. Hanna:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Aftab A. Ansari

Academic Editor

PLOS ONE
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